First-in-Human Phase I Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors.
George D DemetriJason John LukeAntoine HollebecqueJohn D PowderlyAlexander I SpiraVivek SubbiahLouie NaumovskiChris ChenHua FangDominic W LaiHuibin YueAkshanth R PolepallyJames W PurcellRandy RobinsonPadmanee SharmaJames P AllisonAnthony TolcherVictor M VillalobosPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
ABBV-085 appeared safe and tolerable at a dose of 3.6 mg/kg every 14 days, with preliminary antitumor activity noted in patients with osteosarcoma and UPS. Given the high unmet need in these orphan malignancies, further investigation into targeting LRRC15 in these sarcomas may be warranted.